Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...
Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback